Manufacturing biological medicines is generally more complex than the production of traditional (
There is no common European consensus on how to reward healthcare innovation.
Innovative medicines generally benefit from a certain period of intellectual property protection
The biotech industry proposes the development of shared European standards for HTAs to ensure the
Biosimilar medicines are follow-on versions of original biological medicines.
HTA should be based on an in-depth interaction to discuss specific data required in order to deci
A disease is defined as rare in Europe when it affects less than 1 in 2,000 citizens (Orphan Drug
HTAs should be a flexible process used collaboratively. The use of HTA to make reimbursement dec